Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. News
  7. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate

07/15/2021 | 04:44am EDT

The board of directors of Sino Biopharmaceutical Limited announced that "Dexmedetomidine Hydrochloride Injection", an intravenous anesthetic developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People's Republic of China. The product is filed as a Chemicals Category 3 drug and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Dexmedetomidine is an 2 adrenergic receptor agonist with central sympathetic inhibition, anxiolytic and sedative effects; it can be used in general anesthesia, sedation for endotracheal intubation during ventilator treatment and for invasive examinations, as well as cardiovascular surgery anesthesia and perioperative anesthesia combined with other drugs. Dexmedetomidine does not cause respiratory depression during sedation and hypnosis. It is recommended by many domestic and international guidelines and has been included in the national medical insurance, and is one of the mainstream anesthetic drugs in clinical practice. The approval for launch of this product will strengthen the Group's strength in the field of anesthesia.


© S&P Capital IQ 2021
All news about SINO BIOPHARMACEUTICAL LIMITED
09/13SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for quarterly dividend
FA
09/02SINO BIOPHARMACEUTICAL : Receives Registration Approval for Cancer Treatment in ..
MT
09/02SINO BIOPHARMACEUTICAL : Gets Registration Approval for Hepatitis Treatment in C..
MT
09/01Hong Kong Hang Seng Rises 0.6%, Led by Tech Sector
MT
09/01Sino Biopharmaceutical Limited Announces Sofosbuvir Tablets Obtains Drug Regi..
CI
09/01Sino Biopharmaceutical Limited's Lenvatinib Mesilate Capsule Obtains Drug Reg..
CI
08/31Sino Biopharmaceutical Limited Announces Second Ordinary Interim Dividend for..
CI
08/31Sino Biopharmaceutical Limited Reports Earnings Results for the Half Year End..
CI
08/19Hong Kong Hang Seng Down 2.1% on Beijing Regulatory Outlook
MT
08/18Sino Biopharmaceutical Limited Provides Earnings Guidance for the Six Months ..
CI
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Financials
Sales 2021 34 268 M 4 404 M 4 404 M
Net income 2021 9 666 M 1 242 M 1 242 M
Net cash 2021 10 049 M 1 291 M 1 291 M
P/E ratio 2021 13,5x
Yield 2021 2,01%
Capitalization 119 B 15 340 M 15 340 M
EV / Sales 2021 3,19x
EV / Sales 2022 2,54x
Nbr of Employees 24 443
Free-Float 52,3%
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 6,36 HKD
Average target price 10,65 HKD
Spread / Average Target 67,4%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Theresa Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Mao Li Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-15.20%15 340
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604